Inactivated Split Influenza Vaccine

BIOLOGICAL4 trials

Sponsors

Novartis, St. Petersburg Research Institute of Vaccines and Sera

Conditions

InfluenzaSeasonal Influenza

Phase 1

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

CompletedNCT05126979

St. Petersburg Research Institute of Vaccines and SeraInfluenza

Start: 2016-03-09End: 2016-05-13Updated: 2022-01-06

Phase 3

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

CompletedNCT00945841

NovartisSeasonal Influenza

Start: 2009-06-30End: 2009-06-30Updated: 2017-04-07

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

CompletedNCT05089123

St. Petersburg Research Institute of Vaccines and SeraInfluenza

Start: 2020-03-03End: 2020-08-24Updated: 2022-01-06

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

CompletedNCT05317767

St. Petersburg Research Institute of Vaccines and SeraInfluenza

Start: 2020-02-10End: 2020-09-14Updated: 2022-04-08